USPTO serial 87290975
IO?
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- GLASSER, CARYN
- Law office
- TMEG LAW OFFICE 105
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IO??
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lori S. Meddings
Lori S. Meddings Quarles & Brady LLP33 East Main Street, Suite 900Madison, WI 53703UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | (Based on 44(e)) Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; sanitary preparations for medical purposes; vaccines; pharmaceutical and medicinal preparations and substances, namely, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; medical diagnostic reagents and substances, all for in vivo use; antibodies and therapeutic antibodies for use as anti-lymphocytic agents for medical use; pharmaceutical preparations in the form of foams or for use in producing foams, for sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for medical therapeutic and diagnostic purposes; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for use in the treatment of pre-eclampsia; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, and intracranial hemorrhages, cerebral hemorrages, and hematoma; pharmaceutical preparations for the treatment of cancer; pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of multiple neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for the treatment of immune disorders, namely, type 1 diabetes, psoriasis, coeliac disease and rheumatoid arthritis; pharmaceutical preparations for the treatment of sepsis; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; chemical reagents for medical or veterinary therapeutic and medical diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; transarterial chemoembolization pharmaceutical preparations, vaccines and antitoxic sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; Pharmaceutical preparations being beads, including microscopic radioactive beads, for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumors; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents | ACTIVE | — |
| 010 | (Based on 44(e)) Surgical, medical, dental and veterinary apparatus and instruments, namely, cryoablation needles, medical syringes, electrically powered tissue ablation devices, artificial limbs, orthopaedic articles, namely, implants made of artificial materials, haemofiltration devices for medical use, apparatus for generating and transmitting ultrasound for medical and diagnostic use, surgical and medical apparatus and instruments for use in minimally invasive cryoablation procedures, electronic apparatus and instruments for use in relation to ultrasound imaging and scanning for medical and diagnostic use, and medical and diagnostic imaging units; Surgical and medical apparatus, instruments and devices for the treatment of chronic lung disease including emphysema; medical syringes, medical cannula needles, medical tubing; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical and medical apparatus and instruments for producing and administering sclerosing foams; surgical and medical apparatus and instruments for producing foams for use in sclerotherapy, phlebology, angiology or proctology, sterilisation treatment or for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; surgical and medical devices for assessing the physical characteristics of such foams, namely, devices for intravenous administration of foam, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes, medical diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose, and devices for monitoring the position and effect of foam in the human body; medical diagnostic devices for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; drug delivery embolisation apparatus, instruments and systems; apparatus and instruments for use in the circulatory system; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation, namely, medical devices in the nature of particles, namely, embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic glass beads, impregnated with radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices which use ultrasound to enhance drug delivery and/or medically activate drugs; catheters for delivery of drugs or fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology or proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of foam in the human body; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins, hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; surgical instruments and apparatus and medical diagnostic apparatus for use in interventional pulmonology; medical devices for use in pulmonary and thoracic surgery and procedures; medical devices for use in pulmonary and thoracic surgery, namely, lung volume reduction devices; artificial surgical implants for use in interventional pulmonology; surgical implants comprising artificial surgical implants for restoring, maintaining and improving patient breathing, and artificial surgical implants for restoring, maintaining and improving lung function; medical devices for performing cryotherapy, namely, cryosurgical probes and cryoablation needles used for the minimally invasive cryoablation of cancerous and benign tissues; medical apparatus consisting of treatment probes and high pressure valves used for heat or freeze treatment incorporating computer software; surgical instruments and apparatus and medical diagnostic apparatus for use in cryoablation, and the treatment of prostate cancer, kidney or renal tumours, and benign prostatic hyperplasia (BPH ); medical devices used to deliver heat to target sites using electrical current through needles; medical devices to deliver cryogen gas for freezing and either cryogen gas or electrical current for heating for treatment of cancer and tumors; medical devices for ablating human and animal tissue using microwave energy; medical devices for treating cancerous and benign tissue using microwave energy; replacement and structural parts and fittings for all of the aforesaid goods | ACTIVE | — |
| 041 | (Based on 1(b)) Provision of education, namely, training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, developing, arranging and conducting live and online educational conferences, seminars, classes, lectures, panel discussions, workshops and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials in connection therewith; Provision of education and training, namely, conducting online and telephonic instruction and courses in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of education and training, namely, development of multi-media educational content for use with mobile devices and computers in relation to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Arranging, and conducting educational conferences and programs and providing courses of instruction in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision and publication of educational material and content, namely, publication of teaching guides, instructional materials, brochures and providing on-line non-downloadable publications in the nature of teaching guides, instructional materials, and brochures in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Conducting educational seminars in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care and distribution of course materials therewith; Information and advice relating to education and training provided online from a computer database or the internet, all relating to healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; Provision of educational information, namely, providing on-line instruction in the fields healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care provided on-line from a computer database | ACTIVE | — |
| 042 | (Based on 1(b)) Providing on-line, non-downloadable educational software featuring instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine, medical diseases, disorders and related treatments; Information about medical research; Providing educational information in the field of medical research; Providing educational information in the field of medical research by means of computer, electronic and online databases; Information about pharmaceutical research; Providing educational information in the field of pharmaceutical research; Providing educational information in the field of pharmaceutical research by means of computer, electronic and online databases | ACTIVE | — |
| 044 | (Based on 1(b)) Provision of medical and surgical information; Provision of medical and surgical information on-line from a computer database or from the Internet or by telecommunication means; Providing medical information; Providing a website featuring information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing a website featuring medical information regarding medicine, medical treatment, medical patient care, therapeutic properties of prescription drugs, pharmaceutical advice, dispensing of pharmaceuticals, medical treatment and medical patient care aftercare; Providing healthcare information; Providing information about medical devices for use in medical procedures and surgery; Providing information about healthcare; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care; Providing information in the field of healthcare, therapeutic properties of pharmaceuticals, medical devices for use in medical procedures and surgery, surgery, and medicine and medical patient care by means of computer, electronic and online databases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named IO?
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 22, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 22, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 16, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 19, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 18, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 17, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 17, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 3, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 24, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 24, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 7, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 6, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 5, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 5, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 29, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 1, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 29, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 29, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 23, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 22, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 22, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 11, 2021 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jan 11, 2021 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Jan 11, 2021 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jan 11, 2021 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Nov 23, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 23, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 21, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 30, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 30, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 21, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 25, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2020 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 16, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 15, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 15, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 15, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 15, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 31, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 31, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 31, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 10, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 12, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 29, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 3, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 3, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 27, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 27, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 27, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 27, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 23, 2019 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 23, 2019 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Aug 23, 2019 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Aug 23, 2019 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Feb 25, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 25, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 25, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 4, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 4, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 1, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 2, 2018 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 18, 2018 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 8, 2018 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Mar 7, 2018 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 2, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 2, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 2, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 22, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 22, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 7, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 10, 2017 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 9, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jan 27, 2017 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 13, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 9, 2017 | NWAP | NEW APPLICATION ENTERED | — |